UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study

The New England journal of medicine, 2014-08, Vol.371 (8), p.711-722

2014

Link zum Volltext

Verfügbarkeit prüfen

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

Journal of acquired immune deficiency syndromes (1999), 2013-08, Vol.63 (4), p.449

2013

Link zum Volltext

Verfügbarkeit prüfen

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

Arthritis research & therapy, 2022-08, Vol.24 (1), p.1-208, Article 208

2022

Link zum Volltext

Verfügbarkeit prüfen

The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment

Journal of clinical pharmacology, 2015-08, Vol.55 (8), p.944-952

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical drug interaction profile of idelalisib in healthy subjects

Journal of clinical pharmacology, 2015-08, Vol.55 (8), p.909-919

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease

Clinical pharmacokinetics, 2021-08, Vol.60 (8), p.1029-1040

2021

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies

Cancer chemotherapy and pharmacology, 2016, Vol.77 (1), p.89-98

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4633: Pharmacokinetics, metabolism and excretion of idelalisib

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4633-4633

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT217: Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT217-CT217

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT204: The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT204-CT204

2014

Link zum Volltext

Verfügbarkeit prüfen

The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2592-2592

2014

Link zum Volltext

Verfügbarkeit prüfen

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Blood, 2015-12, Vol.126 (23), p.4172-4172

2015

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, Metabolism and Excretion Of Idelalisib

Blood, 2013-11, Vol.122 (21), p.5570-5570

2013

Link zum Volltext

Verfügbarkeit prüfen

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment

Blood, 2013-11, Vol.122 (21), p.5572-5572

2013

Link zum Volltext

Verfügbarkeit prüfen

Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects

Blood, 2013-11, Vol.122 (21), p.5573-5573

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects

Blood, 2013-11, Vol.122 (21), p.5575-5575

2013

Link zum Volltext

Verfügbarkeit prüfen

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment

Blood, 2013-11, Vol.122 (21), p.5571-5571

2013

Link zum Volltext

Verfügbarkeit prüfen

Exposure-response analysis from a Phase 2 study of the Syk inhibitor entospletinib in patients with relapsed or refractory hematologic malignancies

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e13584-e13584

2015

Link zum Volltext

Verfügbarkeit prüfen

Entospletinib drug interaction profile and mass balance

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14097-e14097

2016

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients

Journal of clinical pharmacology, 2016-06, Vol.56 (6), p.723-732

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 32: Single and multiple dose-ranging evaluation of safety, pharmacokinetics, and pharmacodynamics of GS-9973, a novel pSYK inhibitor

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.32-32

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects

Journal of acquired immune deficiency syndromes (1999), 2016-07, Vol.72 (3), p.281

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers

Clinical drug investigation, 2017-02, Vol.37 (2), p.195-205

2017

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic modeling of idelalisib, a novel PI3K[delta] inhibitor, in healthy subjects and patients with hematologic malignancies

Cancer chemotherapy and pharmacology, 2016-01, Vol.77 (1), p.89

2016

Link zum Volltext

Verfügbarkeit prüfen

Drug interaction profile of idelalisib and its major metabolite, GS-563117

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2593-2593

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Humans
(11)
Female
(10)
Male
(10)
Adult
(9)
Middle Aged
(8)
Young Adult
(8)
Pharmacokinetics
(7)
Pharmacology & Pharmacy
(7)
Adolescent
(5)
Infectious Diseases
(4)
Adenine - Analogs & Derivatives
(3)
Adenine - Therapeutic Use
(3)
Aged
(3)
Antineoplastic Agents - Pharmacokinetics
(3)
Antiretroviral Drugs
(3)
Area Under Curve
(3)
Biological And Medical Sciences
(3)
Clinical Trials
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment

Clinical drug interaction profile of idelalisib in healthy subjects

Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease

Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies

Abstract 4633: Pharmacokinetics, metabolism and excretion of idelalisib

Abstract CT217: Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects

Abstract CT204: The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment

The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Pharmacokinetics, Metabolism and Excretion Of Idelalisib

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment

Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects

Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects

The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment

Exposure-response analysis from a Phase 2 study of the Syk inhibitor entospletinib in patients with relapsed or refractory hematologic malignancies

Entospletinib drug interaction profile and mass balance

Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients

Abstract 32: Single and multiple dose-ranging evaluation of safety, pharmacokinetics, and pharmacodynamics of GS-9973, a novel pSYK inhibitor

Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects

Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers

Population pharmacokinetic modeling of idelalisib, a novel PI3K[delta] inhibitor, in healthy subjects and patients with hematologic malignancies

Drug interaction profile of idelalisib and its major metabolite, GS-563117

Suchergebnisse filtern